Boehringer Ingelheim to acquire NBE-Therapeutics for €1.1bn
German pharma company Boehringer Ingelheim has signed a deal worth €1.18 billion to acquire NBE-Therapeutics, a clinical-stage Switzerland-based biotech company, focused on developing antibody-drug conjugates (ADCs) and advancing targeted cancer therapies. Through the acquisition, Boehringer Ingelheim will gain access to the Swiss firm’s iADC platform, which is capable of creating immune stimulatory ADCs with an […]